Development of a LC-MS/MS Method for a New Ortho-aryl Chalcone Compound of OC26 and its Application to Bile

Lexing Chen; Jiang Liu; Xia Gan; Zhounan Jiang; Jun Xu; Shaohui Cai

Development of a LC-MS/MS Method for a New Ortho-aryl Chalcone Compound of OC26 and its Application to Bile

Lexing Chen, Jiang Liu, Xia Gan, Zhounan Jiang, Jun Xu, Shaohui Cai

Abstract

Background OC26 and its pro-drug BOC26P, both ortho-aryl chalcone compounds, showed a well-defined antitumor activity in various cancer cells especially in drug-resistant tumor cell lines.

Aim The purpose of this study was to investigate the bile excretion characteristics of OC26 after OC26 and BOC26P administered in rats respectively.

Method An ultra-performance liquid chromatography/tandem mass spectrometry (UPLC-MS/MS) method was developed and validated for OC26 in rat bile. Liquid-liquid extraction with ethyl acetate method was use to pretreat the bile samples. After that, a gradient mobile phase at a flow rate 0.5mL/min of acetonitrile and 2mM CH₃COONH₄ with 0.1% aqueous ammonia solution (v/v) and the positive ion alternate mode separated and quantified OC26. Bile samples were collected from rats after intravenous injection (i.v) 12.5mg/kg of OC26 and BOC26P, respectively.

Results For method validation, the method showed high extraction recovery. The assay showed a good linearity with correlation coefficient >0.99 at the concentration ranges of 20-2000ng/mL. All data were within the required limits. The bile excretion results showed that the excretion amount of OC26 was gradually stabilized after 2h. The accumulative excretion percentage of OC26 after i.v 12.5mg/kg BOC26P was significantly higher than that of OC26 after i.v 12.5mg/kg OC26. Significant gender differences were also observed in bile excretion of OC26.

Conclusion This method was selective, sensitive and reliable and successfully applied to the bile excretion of OC26. This study provided theoretical basis for OC26 further research.

Keywords

OC26, BOC26P, LC-MS/MS, Bile excretion, Active metabolite.

Full Text:

References

Brouhard GJ, Rice LM. The contribution of alpha beta-tubulin curvature to microtubule dynamics. J Cell Biol. 2014; 207 (3): 323-34.

Tangutur AD, Kumar D, Krishna KV, Kantevari S. Microtubule targeting agents as cancer chemotherapeutics: An overview of molecular hybrids as stabilizing and destabilizing agents. Curr. Top. Med. Chem.. 2017; 17 (22): 2523-37.

Asteriou E, Gkoutzourelas A, Mavropoulos A, Katsiari C, Sakkas LI, Bogdanos DP. Curcumin for the management of periodontitis and early ACPA-positive rheumatoid arthritis: Killing two birds with one stone. Nutrients. 2018; 10 (7).

Burmaoglu S, Yilmaz AO, Polat MF, Kaya R, Gulcin I, Algul O. Synthesis and biological evaluation of novel tris-chalcones as potent carbonic anhydrase, acetylcholinesterase, butyrylcholinesterase and alpha-glycosidase inhibitors. Bioorg. Chem.. 2019; 85: 191-7.

Salum LB, Mascarello A, Canevarolo RR, Altei WF, Laranjeira ABA, Neuenfeldt PD, et al. N-(1 '-naphthyl)-3,4,5-trimethoxybenzohydrazide as microtubule destabilizer: Synthesis, cytotoxicity, inhibition of cell migration and in vivo activity against acute lymphoblastic leukemia. Eur. J. Med. Chem.. 2015; 96: 504-18.

Gan PP, McCarroll JA, Po'uha ST, Kamath K, Jordan MA, Kavallaris M. Microtubule dynamics, mitotic arrest, and apoptosis: Drug-induced differential effects of beta III-tubulin. J.Mol. Cancer Ther.. 2010; 9 (5): 1339-48.

Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nature Reviews Cancer. 2004; 4 (4): 253-65.

Bates D and Eastman A. Microtubule destabilising agents: Far more than just antimitotic anticancer drugs. Br. J. Clin. Pharmacol.. 2017; 83 (2): 255-68.

Zhu C, Zuo Y, Wang R, Liang B, Yue X, Wen G, et al. Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence. J. Med. Chem.. 2014; 57 (15): 6364-82.

Zhu CG, Wang RM, Zheng WC, Chen DY, Yue X, Cao YN, et al. Synthesis and evaluation of anticancer activity of BOC26P, an ortho-aryl chalcone sodium phosphate as water-soluble prodrugs in vitro and in vivo. J. Biomed. Pharmacother. 2017; 96: 551-62.

Aungst BJ. Optimizing oral bioavailability in drug discovery: An overview of design and testing strategies and formulation options. J. Pharm. Sci.. 2017; 106 (4): 921-9.

Latheef SAA, Devanabanda M, Sankati S, Ramanadham M. Differential expression of alkaline phosphatase gene in proliferating primary lymphocytes and malignant lymphoid cell lines. Immunol Lett. 2016; 170: 37-41.

Mikah P, Krabbe L-M, Eminaga O, Herrmann E, Papavassilis P, Hinkelammert R, et al. Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer. BMC Cancer. 2016; 16.

Orimo H, Shimada T. Effects of phosphates on the expression of tissue-nonspecific alkaline phosphatase gene and phosphate-regulating genes in short-term cultures of human osteosarcoma cell lines. Mol. Cell. Biochem.. 2006; 282 (1-2): 101-8.

Orimo H, Shimada T. The role of tissue-nonspecific alkaline phosphatase in the phosphate-induced activation of alkaline phosphatase and mineralization in SaOS-2 human osteoblast-like cells. Mol. Cell. Biochem.. 2008; 315 (1-2): 51-60.

Rao SR, Snaith AE, Marino D, Cheng X, Lwin S T, Orriss I R, et al. Tumour-derived alkaline phosphatase regulates tumour growth, epithelial plasticity and disease-free survival in metastatic prostate cancer. Br. J. Cancer. 2017; 116 (2): 227-36.

Sanches BMA, Ferreira EI. Is prodrug design an approach to increase water solubility?. Int. J. Pharm.. 2019; 568.

Czerniak R. Gender-based differences in pharmacokinetics in laboratory animal models. Int. J. Toxicol.. 2001; 20 (3): 161-3.

Ding M, Zhang YM, Wang XD, Zhao YQ. Gender-related differences in pharmacokinetics, tissue distribution, and excretion of 20(R)-25-methoxyl-dammarane-3 beta,12 beta,20-triol and its metabolite in rats and anti-ovarian cancer evaluation. J. Pharm. Biomed. Anal.. 2018; 158: 327-38.

Martignoni M, Groothuis GMM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin. Drug Metab. Toxicol.. 2006; 2 (6): 875-94.

Refbacks

There are currently no refbacks.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Journal of Pharmaceutical and Biomedical Sciences